Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H29NO5 |
Molecular Weight | 327.4159 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCCN)[C@@H]2C)O4
InChI
InChIKey=HPGHCIXRRLNXRN-XQLAAWPRSA-N
InChI=1S/C17H29NO5/c1-10-4-5-13-11(2)14(19-9-8-18)20-15-17(13)12(10)6-7-16(3,21-15)22-23-17/h10-15H,4-9,18H2,1-3H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
Molecular Formula | C17H29NO5 |
Molecular Weight | 327.4159 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:03:59 GMT 2023
by
admin
on
Sat Dec 16 17:03:59 GMT 2023
|
Record UNII |
2TF7EGV39I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2TF7EGV39I
Created by
admin on Sat Dec 16 17:03:59 GMT 2023 , Edited by admin on Sat Dec 16 17:03:59 GMT 2023
|
PRIMARY | |||
|
10019350
Created by
admin on Sat Dec 16 17:03:59 GMT 2023 , Edited by admin on Sat Dec 16 17:03:59 GMT 2023
|
PRIMARY | |||
|
SM-934
Created by
admin on Sat Dec 16 17:03:59 GMT 2023 , Edited by admin on Sat Dec 16 17:03:59 GMT 2023
|
PRIMARY | SM 934: CAS NO 133162-25-1For Autoimmune diseases, SLESM934, an artemisinin derivative, possesses potent antiproliferative and antiinflammatory properties | ||
|
133162-24-0
Created by
admin on Sat Dec 16 17:03:59 GMT 2023 , Edited by admin on Sat Dec 16 17:03:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
RESULTS: In vitro, SM934 inhibited interferon-.GAMMA. (IFN.GAMMA.) and interleukin-17 (IL-17) production from polyclonal CD4+ T cells activated by T cell receptor engagement and the differentiation of naive CD4+ T cells into Th1 and Th17 cells, but not Treg cells. In vivo, 12-week-old MRL/lpr mice treated with SM934 for 4 weeks showed significantly ameliorated proteinuria and renal lesion severity, decreased levels of blood urea nitrogen, serum IFN.GAMMA., and serum anti-double-stranded DNA antibodies, decreased spleen size and a lower percentage of CD3+B220+CD4-CD8- T cells, 16-week-old MRL/lpr mice treated with SM934 for 8 weeks avoided severe proteinuria and survived longer. Ex vivo, SM934 treatment elevated the percentage of Treg cells, inhibited the development of Th1 and Th17 cells, and impeded the comprehensive activation of STAT-1, STAT-3, and STAT-5 proteins in splenocytes.
|